Fig. 1From: The siRNA-mediated knockdown of AP-1 restores the function of the pulmonary artery and the right ventricle by reducing perivascular and interstitial fibrosis and key molecular players in cardiopulmonary diseaseSchematic illustration of experimental animal models obtained for a period of 12 weeks. Golden Syrian hamsters (39 males, 3 months old) were randomly divided into three experimental groups, including: (1) C group, healthy animals; (2) MCT group obtained by a single subcutaneous injection dose of 60 mg/kg monocrotaline (MCT) at the beginning of the experiment (day 0); (3) MCT-siRNA AP-1 group that received subcutaneous injections of 100 nM siRNA AP-1 every two weeks. All animal groups received water and standard chow ad libitumBack to article page